FIELD: biotechnology; immunology; virology.
SUBSTANCE: disclosed is an immunobiological agent based on a vector mRNA, wherein the mRNA comprises a sequence selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:9 on 5’ end; an open reading frame encoding an S antigen of the SARS-CoV-2 virus; sequence SEQ ID NO:6 or SEQ ID NO:7 on 3’ end, as well as mRNA, which contains a sequence selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:9 on 5’ end; open reading frame coding antigen of influenza A H1N1 virus; sequence SEQ ID NO:6 or SEQ ID NO:7 on 3’ end.
EFFECT: invention makes it possible to create a safe immunobiological agent based on mRNA vector, which provides induction of a complex immune response against SARS-CoV-2 virus and influenza virus.
5 cl, 5 dwg, 10 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| EXPRESSION VECTOR BASED ON HUMAN ADENOVIRUS 19 SEROTYPE AND METHOD OF ITS APPLICATION | 2023 |
|
RU2811791C1 |
| VACCINE AGAINST INFLUENZA TYPE A, INFLUENZA TYPE B AND COVID-19 | 2021 |
|
RU2751485C1 |
| EXPRESSION VECTOR BASED ON ADENO-ASSOCIATED VIRUS CARRYING RECOMBINANT ANTIBODY GENES AND ITS USE FOR PREVENTION OF DISEASES CAUSED BY INFLUENZA A VIRUS AND SARS-CoV-2 VIRUS | 2023 |
|
RU2817792C1 |
| mRNA-BASED VECTOR FOR INCREASED TARGET PROTEIN PRODUCTION IN MAMMALIAN CELLS (VARIANTS) | 2022 |
|
RU2792231C1 |
| RECOMBINANT INFLUENZA VIRUS INTENDED FOR THE PREVENTION OF COVID-19 AND INFLUENZA, METHOD OF ITS PRODUCTION AND USE | 2022 |
|
RU2802058C1 |
| ARTIFICIAL GENE CODING A BICISTRONIC STRUCTURE FORMED BY RECEPTOR-BINDING DOMAIN SEQUENCES OF THE GLYCOPROTEIN S OF THE SARS-COV-2 CORONAVIRUS, P2A-PEPTIDE AND GLYCOPROTEIN G VSV, RECOMBINANT PLASMID PSTEM-RVSV-STBL_RBD_SC2, PROVIDING EXPRESSION OF ARTIFICIAL GENE, AND A RECOMBINANT STRAIN OF VESICULAR STOMATITIS VIRUS RVSV-STBL_RBD_SC2, USED TO CREATE A VACCINE AGAINST SARS-COV-2 CORONAVIRUS | 2020 |
|
RU2733831C1 |
| PENTAVALENT SUBUNIT VACCINE AGAINST RESPIRATORY INFECTIONS AND METHOD OF ITS PREPARATION | 2022 |
|
RU2804948C2 |
| ARTIFICIAL GENE STBL_RBD_TRM_SC2, CODING A BICISTRONIC STRUCTURE FORMED BY THE SARS-COV-2 CORONAVIRUS GLYCOPROTEIN S RECEPTOR-BINDING DOMAIN SEQUENCES, TRANSMEMBRANE REGION, P2A-PEPTIDE AND GLYCOPROTEIN G VSV, RECOMBINANT PLASMID PSTEM-RVSV-STBL_RBD_TRM_SC2, PROVIDING EXPRESSION OF ARTIFICIAL GENE, AND A RECOMBINANT STRAIN OF VESICULAR STOMATITIS VIRUS RVSV-STBL_RBD_TRM_SC2, USED TO CREATE A VACCINE AGAINST SARS-COV-2 CORONAVIRUS | 2020 |
|
RU2733832C1 |
| IMMUNOBIOLOGICAL AGENT AND METHOD FOR ITS USE FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST VIRUSES SARS-COV-2 VARIANT B.1.617.2 (DELTA) AND SARS-COV-2 VARIANT B.1.1.529 (OMICRON) (VARIANTS) | 2022 |
|
RU2779634C1 |
| IMMUNOBIOLOGICAL AGENT FOR THERAPY OF ONCOLOGICAL DISEASES BASED ON mRNA VECTOR | 2024 |
|
RU2828631C1 |
